Adaptive Biotechnologies reports Q4 EPS (9c), consensus (18c)

Reports Q4 revenue $71.68M, consensus $60.9M. The MRD business, which contributed 86% of revenue in the fourth quarter and 77% of revenue in the full year, grew 54% and 46% over the corresponding periods a year ago. “2025 was an outstanding year for Adaptive, marked by strong execution and meaningful progress across the business,” said Chad Robins, chief executive officer and co-founder of Adaptive Biotechnologies (ADPT). “We delivered 46% revenue growth and achieved profitability in our MRD business, while advancing our Immune Medicine platform through scaled TCR-antigen data generation and two data partnerships. As we enter 2026, we are well positioned to drive continued growth, expand margins and achieve company-wide profitability, enabled by disciplined capital allocation and a strong financial foundation.”